Anti-CD200R1 Monoclonal Antibody, Clone OX-102 [FITC] (CABT-47295MR) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use

Total Page：16

File Type：pdf, Size：1020Kb

Anti-CD200R1 monoclonal antibody, clone OX-102 [FITC] (CABT-47295MR) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Product Overview Mouse anti Rat CD200 Receptor 1 antibody, clone OX-102 recognizes the rat OX2 (CD200) receptor 1. This antigen is a heavily glycosylated 60-100kDa cell surface molecule expressed by cells of the myeloid lineage but not by T or B lymphocytes. Mouse anti Rat CD200 Receptor 1 antibody, clone OX-102 has been shown to block the interaction of OX2 receptor 1 with CD200. Flow Cytometry Use 10ul of the suggested working dilution to label 106 cells in 100ul. Specificity CD200R1 Immunogen Membrane fraction of thioglycollate-elicited rat peripheral cells. Isotype IgG1 Source/Host Mouse Species Reactivity Rat Clone OX-102 Conjugate FITC Applications FC Procedure Conjugated Antibodies Format Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid Size 100 μg Preservative See individual product datasheet Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. Warnings For research purposes only GENE INFORMATION 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved Gene Name Cd200r1 CD200 receptor 1 [ Rattus norvegicus (Norway rat) ] Official Symbol CD200R1 Synonyms CD200R1; CD200 receptor 1; Mox2r; cell surface glycoprotein CD200 receptor 1; OX2 receptor; OX102 antigen; CD200 cell surface glycoprotein receptor; cell surface glycoprotein OX2 receptor 1; antigen identified by monoclonal antibody MRC OX-2 receptor; Entrez Gene ID 64357 Protein Refseq NP_076443 UniProt ID Q9ES58 Chromosome Location 11q21 Pathway Adaptive Immune System; Immune System; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell; Function receptor activity; 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 2 © Creative Diagnostics All Rights Reserved.

Copy Link

Recommended publications

Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma
Anatomy and Pathology Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma Sarah L. Lake,1 Sarah E. Coupland,1 Azzam F. G. Taktak,2 and Bertil E. Damato3 PURPOSE. To detect deletions and loss of heterozygosity of disease is fatal in 92% of patients within 2 years of diagnosis. chromosome 3 in a rare subset of fatal, disomy 3 uveal mela- Clinical and histopathologic risk factors for UM metastasis noma (UM), undetectable by fluorescence in situ hybridization include large basal tumor diameter (LBD), ciliary body involve- (FISH). ment, epithelioid cytomorphology, extracellular matrix peri- ϩ ETHODS odic acid-Schiff-positive (PAS ) loops, and high mitotic M . Multiplex ligation-dependent probe amplification 3,4 5 (MLPA) with the P027 UM assay was performed on formalin- count. Prescher et al. showed that a nonrandom genetic fixed, paraffin-embedded (FFPE) whole tumor sections from 19 change, monosomy 3, correlates strongly with metastatic death, and the correlation has since been confirmed by several disomy 3 metastasizing UMs. Whole-genome microarray analy- 3,6–10 ses using a single-nucleotide polymorphism microarray (aSNP) groups. Consequently, fluorescence in situ hybridization were performed on frozen tissue samples from four fatal dis- (FISH) detection of chromosome 3 using a centromeric probe omy 3 metastasizing UMs and three disomy 3 tumors with Ͼ5 became routine practice for UM prognostication; however, 5% years’ metastasis-free survival. to 20% of disomy 3 UM patients unexpectedly develop metas- tases.11 Attempts have therefore been made to identify the RESULTS. Two metastasizing UMs that had been classified as minimal region(s) of deletion on chromosome 3.12–15 Despite disomy 3 by FISH analysis of a small tumor sample were found these studies, little progress has been made in defining the key on MLPA analysis to show monosomy 3.
[Show full text]
Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
[Show full text]
Investigating the Role of PIR1 and CD200R1 in the Innate Immune Response to Viral Pathogens
University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2017-05-30 Investigating the Role of PIR1 and CD200R1 in the Innate Immune Response to Viral Pathogens Christopher R. MacKay University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Immunity Commons, Immunology of Infectious Disease Commons, Pathogenic Microbiology Commons, and the Virology Commons Repository Citation MacKay CR. (2017). Investigating the Role of PIR1 and CD200R1 in the Innate Immune Response to Viral Pathogens. GSBS Dissertations and Theses. https://doi.org/10.13028/M2602R. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/901 Creative Commons License This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. INVESTIGATING THE ROLE OF PIR1 AND CD200R1 IN THE INNATE IMMUNE RESPONSE TO VIRAL PATHOGENS A Dissertation Presented by CHRISTOPHER ROBERT MACKAY Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences, Worcester in partial fulﬁllment of the requirements for the degree of DOCTOR OF PHILOSOPHY May 30, 2017 M.D./Ph.D. Program INVESTIGATING THE ROLE OF PIR1 AND CD200R1 IN THE INNATE IMMUNE RESPONSE TO VIRAL PATHOGENS A Dissertation Presented by CHRISTOPHER ROBERT MACKAY The signatures of the Dissertation Defense Committee signiﬁes completion and approval as to style and content of the Dissertation Evelyn A.
[Show full text]
Uniprot Nr. Proseek Panel 2,4-Dienoyl-Coa Reductase, Mitochondrial
Protein Name (Short Name) Uniprot Nr. Proseek Panel 2,4-dienoyl-CoA reductase, mitochondrial (DECR1) Q16698 CVD II 5'-nucleotidase (5'-NT) P21589 ONC II A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAM-TS13) Q76LX8 CVD II A disintegrin and metalloproteinase with thrombospondin motifs 15 (ADAM-TS 15) Q8TE58 ONC II Adenosine Deaminase (ADA) P00813 INF I ADM (ADM) P35318 CVD II ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) P28907 NEU I Agouti-related protein (AGRP) O00253 CVD II Alpha-2-macroglobulin receptor-associated protein (Alpha-2-MRAP) P30533 NEU I Alpha-L-iduronidase (IDUA) P35475 CVD II Alpha-taxilin (TXLNA) P40222 ONC II Aminopeptidase N (AP-N) P15144 CVD III Amphiregulin (AR) P15514 ONC II Angiopoietin-1 (ANG-1) Q15389 CVD II Angiopoietin-1 receptor (TIE2) Q02763 CVD II Angiotensin-converting enzyme 2 (ACE2) Q9BYF1 CVD II Annexin A1 (ANXA1) P04083 ONC II Artemin (ARTN) Q5T4W7 INF I Axin-1 (AXIN1) O15169 INF I Azurocidin (AZU1 P20160 CVD III BDNF/NT-3 growth factors receptor (NTRK2) Q16620 NEU I Beta-nerve growth factor (Beta-NGF) P01138 NEU I, INF I Bleomycin hydrolase (BLM hydrolase) Q13867 CVD III Bone morphogenetic protein 4 (BMP-4) P12644 NEU I Bone morphogenetic protein 6 (BMP-6) P22004 CVD II Brain-derived neurotrophic factor (BDNF) P23560 NEU I, INF I Brevican core protein (BCAN) Q96GW7 NEU I Brorin (VWC2) Q2TAL6 NEU I Brother of CDO (Protein BOC) Q9BWV1 CVD II Cadherin-3 (CDH3) P22223 NEU I Cadherin-5 (CDH5) P33151 CVD III Cadherin-6 (CDH6) P55285 NEU I Carbonic anhydrase 5A, mitochondrial
[Show full text]
MAFB Determines Human Macrophage Anti-Inflammatory
MAFB Determines Human Macrophage Anti-Inflammatory Polarization: Relevance for the Pathogenic Mechanisms Operating in Multicentric Carpotarsal Osteolysis This information is current as of October 4, 2021. Víctor D. Cuevas, Laura Anta, Rafael Samaniego, Emmanuel Orta-Zavalza, Juan Vladimir de la Rosa, Geneviève Baujat, Ángeles Domínguez-Soto, Paloma Sánchez-Mateos, María M. Escribese, Antonio Castrillo, Valérie Cormier-Daire, Miguel A. Vega and Ángel L. Corbí Downloaded from J Immunol 2017; 198:2070-2081; Prepublished online 16 January 2017; doi: 10.4049/jimmunol.1601667 http://www.jimmunol.org/content/198/5/2070 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2017/01/15/jimmunol.160166 Material 7.DCSupplemental References This article cites 69 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/198/5/2070.full#ref-list-1 by guest on October 4, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.
[Show full text]
Ethanol Activates Immune Response in Lymphoblastoid Cells
Accepted Manuscript Ethanol Activates Immune Response In Lymphoblastoid Cells Jeanette N. McClintick, Jay A. Tischfield, Li Deng, Manav Kapoor, Xiaoling Xuei, Howard J. Edenberg PII: S0741-8329(18)30284-2 DOI: https://doi.org/10.1016/j.alcohol.2019.01.001 Reference: ALC 6885 To appear in: Alcohol Received Date: 4 October 2018 Revised Date: 21 December 2018 Accepted Date: 3 January 2019 Please cite this article as: McClintick J.N., Tischfield J.A., Deng L., Kapoor M., Xuei X. & Edenberg H.J., Ethanol Activates Immune Response In Lymphoblastoid Cells, Alcohol (2019), doi: https:// doi.org/10.1016/j.alcohol.2019.01.001. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT ETHANOL ACTIVATES IMMUNE RESPONSE IN LYMPHOBLASTOID CELLS Jeanette N. McClintick a, Jay A. Tischfield b, Li Deng b, Manav Kapoor c, Xiaoling Xuei d, Howard J. Edenberg a,d aDepartment of Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, United States bDepartment of Genetics and the Human Genetics Institute of New Jersey, Rutgers, the State University of New Jersey, Piscataway, NJ 08854, United States cDepartments of Neuroscience, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029,MANUSCRIPT United States dDepartment of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, United States Address correspondence to: Jeanette McClintick Dept.
[Show full text]
Inhibition of CD200R1 Expression by C/EBP Beta in Reactive Microglial Cells
Dentesano et al. Journal of Neuroinflammation 2012, 9:165 JOURNAL OF http://www.jneuroinflammation.com/content/9/1/165 NEUROINFLAMMATION RESEARCH Open Access Inhibition of CD200R1 expression by C/EBP beta in reactive microglial cells Guido Dentesano1, Marco Straccia1,2, Aroa Ejarque-Ortiz1, Josep M Tusell1, Joan Serratosa1, Josep Saura2 and Carme Solà1* Abstract Background: In physiological conditions, it is postulated that neurons control microglial reactivity through a series of inhibitory mechanisms, involving either cell contact-dependent, soluble-factor-dependent or neurotransmitter-associated pathways. In the current study, we focus on CD200R1, a microglial receptor involved in one of these cell contact-dependent mechanisms. CD200R1 activation by its ligand, CD200 (mainly expressed by neurons in the central nervous system),is postulated to inhibit the pro-inflammatory phenotype of microglial cells, while alterations in CD200-CD200R1 signalling potentiate this phenotype. Little is known about the regulation of CD200R1 expression in microglia or possible alterations in the presence of pro-inflammatory stimuli. Methods: Murine primary microglial cultures, mixed glial cultures from wild-type and CCAAT/enhancer binding protein β (C/EBPβ)-deficient mice, and the BV2 murine cell line overexpressing C/EBPβ were used to study the involvement of C/EBPβ transcription factor in the regulation of CD200R1 expression in response to a proinflammatory stimulus (lipopolysaccharide (LPS)). Binding of C/EBPβ to the CD200R1 promoter was determined by quantitative chromatin immunoprecipitation (qChIP). The involvement of histone deacetylase 1 in the control of CD200R1 expression by C/EBPβ was also determined by co-immunoprecipitation and qChIP. Results: LPS treatment induced a decrease in CD200R1 mRNA and protein expression in microglial cells, an effect that was not observed in the absence of C/EBPβ.
[Show full text]
Analysis of Intra-Tumoral Macrophages and T Cells in Non-Small Cell Lung Cancer (NSCLC) Indicates a Role for Immune Checkpoint and CD200-CD200R Interactions
cancers Article Analysis of Intra-Tumoral Macrophages and T Cells in Non-Small Cell Lung Cancer (NSCLC) Indicates a Role for Immune Checkpoint and CD200-CD200R Interactions Anders Tøndell 1,2,* , Yashwanth Subbannayya 2,3 , Sissel Gyrid Freim Wahl 2,4, Arnar Flatberg 2,5, Sveinung Sørhaug 1, Magne Børset 2,6 and Markus Haug 2,3,7 1 Department of Thoracic Medicine, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway; [email protected] 2 Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway; [email protected] (Y.S.); [email protected] (S.G.F.W.) arnar.fl[email protected] (A.F.); [email protected] (M.B.); [email protected] (M.H.) 3 Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, 7491 Trondheim, Norway 4 Department of Pathology, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway 5 Central Administration, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway 6 Department of Immunology and Transfusion Medicine, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway 7 Department of Infectious Diseases, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway * Correspondence: [email protected] or [email protected] Citation: Tøndell, A.; Subbannayya, Y.; Wahl, S.G.F.; Flatberg, A.; Sørhaug, Simple Summary: Lung cancer is the leading cause of cancer-related death worldwide, accounting S.; Børset, M.; Haug, M. Analysis of for nearly one-fifth of all cancer-related deaths. Immunotherapy with immune checkpoint inhibitors Intra-Tumoral Macrophages and T has become one of the most promising approaches in the treatment of advanced lung cancer, although Cells in Non-Small Cell Lung Cancer beneficial responses are seen only in a proportion of patients.
[Show full text]
Anti-CD200R1 Monoclonal Antibody, Clone OX108 (CABT-47309MH) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
Anti-CD200R1 monoclonal antibody, clone OX108 (CABT-47309MH) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Product Overview Mouse anti Human CD200R antibody, clone OX108 recognizes human CD200R, a cell surface glycoprotein (also known as OX2R). In humans CD200R is expressed primarily by peripheral blood monocytes and neutrophils but also by other leucocytes including T-lymphocytes and mast cells. Studies suggest that CD200-CD200R interaction may be involved in the control of myeloid cellular function. Levels of expression on resting perispheral blood cells are relatively low. Flow Cytometry Use 10ul of the suggested working dilution to label 106 cells in 100ul Specificity CD200R1 Immunogen Fusion protein hCD200RCD4d3+4 Isotype IgG1 Source/Host Mouse Species Reactivity Human Clone OX108 Conjugate Unconjugated Applications FC Format Purified IgG - liquid Size 200 μg Preservative 0.09% Sodium Azide Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. Warnings For research purposes only GENE INFORMATION 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved Gene Name CD200R1 CD200 receptor 1 [ Homo sapiens (human) ] Official Symbol CD200R1 Synonyms CD200R1; CD200 receptor 1; OX2R; MOX2R; CD200R; HCRTR2; cell surface glycoprotein
[Show full text]
Sequencing of Over 100,000 Individuals Identifies Multiple Genes and Rare Variants Associated with Crohns Disease Susceptibility
medRxiv preprint doi: https://doi.org/10.1101/2021.06.15.21258641; this version posted July 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Sequencing of over 100,000 individuals identifies multiple genes and rare variants associated with Crohns disease susceptibility Aleksejs Sazonovs1*, Christine R. Stevens2,3,4*, Guhan R. Venkataraman5*, Kai Yuan3,4*, Brandon Avila3,6, Maria T. Abreu7, Tariq Ahmad8, Matthieu Allez9, Ashwin N. Ananthakrishnan 10, Gil Atzmon11,12, Aris Baras13, Jeffrey C. Barrett14, Nir Barzilai12,15, Laurent Beaugerie16, Ashley Beecham17,18, Charles N. Bernstein19, Alain Bitton20, Bernd Bokemeyer21, Andrew Chan22,23, Daniel Chung24, Isabelle Cleynen25, Jacques Cosnes26, David J. Cutler27,28,29, Allan Daly30, Oriana M. Damas31, Lisa W. Datta32, Noor Dawany33, Marcella Devoto33,34,35, Sheila Dodge36, Eva Ellinghaus37, Laura Fachal1, Martti Farkkila38, William Faubion39, Manuel Ferreira13, Denis Franchimont40, Stacey B. Gabriel36, Michel Georges41, Kyle Gettler42, Mamta Giri42, Benjamin Glaser43, Siegfried Goerg44, Philippe Goyette45, Daniel Graham46,47,48, Eija Hämäläinen49, Talin Haritunians50, Graham A. Heap8, Mikko Hiltunen51, Marc Hoeppner52, Julie E. Horowitz53, Peter Irving54,55, Vivek Iyer30, Chaim Jalas56, Judith Kelsen33, Hamed Khalili22, Barbara S. Kirschner57, Kimmo Kontula58, Jukka T. Koskela49, Subra Kugathasan28, Juozas Kupcinskas59, Christopher A. Lamb60,61, Matthias Laudes44, Adam P. Levine62, James Lewis63,64, Claire Liefferinckx40, Britt-Sabina Loescher37, Edouard Louis65, John Mansfield60,61, Sandra May37, Jacob L. McCauley17,18, Emebet Mengesha50, Myriam Mni41, Paul Moayyedi66, Christopher J.
[Show full text]
The Role of Mechanism of Action of CD200: CD200R1 Interaction In
The Role and Mechanism of Action of CD200:CD200R1 Interaction in Breast Cancer by Anna Podnos A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Institute of Medical Science University of Toronto © Copyright by Anna Podnos 2015 The Role and Mechanism of Action of CD200:CD200R Interaction in Breast Cancer Anna Podnos PhD Institute of Medical Science University of Toronto 2015 Abstract Cancer cells can use immune inhibitory receptors to evade the host’s anti-tumour responses and establish immunosuppressive networks in the tumour microenvironment. In this thesis, we investigated the interaction between the immunosuppressive molecule CD200 with its receptor, CD200R1, in breast cancer. We found that CD200 is expressed in the local tumour microenvironment in human breast cancer patients and developed a mouse model to study the effect of CD200 on tumour growth and metastasis. Using mouse-derived EMT6 breast cancer cells and BALB/c female hosts, we explored the effects of overexpressing and silencing the expression of CD200 and CD200R1 in hosts and tumour cells. CD200 expression by host and tumour cells enhanced tumour growth and metastasis to draining lymph nodes (DLN). Silencing CD200 expression in EMT6 tumour cells led to a reduction in primary tumour size and metastasis, as well as an increase in anti-tumour cytotoxic responses in the host. Lack of CD200R1 expression in the host resulted in a marked decrease in breast cancer development and CD200R1-/- mice were able to mount specific anti-EMT6 immune response that could be adoptively transferred to wild type naïve hosts. In addition, we extended our findings to a model in which anti-tumour immunity was explored in EMT6 tumour-bearing ii hosts lacking CD200 expression and treated with a combination of immunotherapy with the non- conventional chemotherapeutic agent, metformin.
[Show full text]
CD200 As a Prognostic Factor in Acute Myeloid Leukaemia
Letters to the Editor 566 6 Lamballe F, Tapley P, Barbacid M. TrkC encodes multiple 8 Liu Q, Schwaller J, Kutok J, Cain D, Aster JC, Williams IR et al. neurotrophin-3 receptors with distinct biological properties and Signal transduction and transforming properties of the TEL-TRKC substrate specificities. EMBO J 1993; 12: 3083–3094. fusions associated with t(12;15)(p13;q25) in congenital fibro- 7 Tsoulfas P, Stephens RM, Kaplan DR, Parada LF. TrkC isoforms with sarcoma and acute myelogenous leukemia. EMBO J 2000; 19: inserts in the kinase domain show impaired signaling responses. 1827–1838. J Biol Chem 1996; 271: 5691–5697. Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) CD200 as a prognostic factor in acute myeloid leukaemia Leukemia (2007) 21, 566–568. doi:10.1038/sj.leu.2404559; abnormalities showed that CD200 was significantly associated published online 25 January 2007 with worse survival (HR 1.68, 95% CI 1.08–2.62, P ¼ 0.02; Figure 1a and b). The CD200 gene (aka MOX-2, OX-2) is located on chromosome 3 and encodes a type-1 membrane glycoprotein.1 This protein belongs to the immunoglobulin superfamily and is expressed on many different cell types including T and B lymphocytes and dendritic cells.2 CD200 binds multiple membrane receptor isoforms (CD200R) which have a more tissue restricted expression.3,4 The best characterized isoform, CD200R1, has a longer cytoplasmic tail containing three conserved tyrosine residues that can be phosphorylated.1 These phosphorylated residues interact
[Show full text]